Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA Methylation Signatures Differentiate Meningiomas from Normal Dura [OmniSNP]

ABSTRACT: Meningiomas are the most common primary brain tumor. Though typically benign with a low mutational burden, histopathologic analysis has poor predictive value for malignant behavior and there are no proven chemotherapies. Although DNA methylation patterns distinguish subgroups of meningiomas and have higher predictive value for tumor behavior than histologic classification, little is known about differences in DNA methylation between meningiomas and surrounding normal dura tissue. Using multimodal studies of meningioma/dura pairs, we identified 4 distinct DNA methylation patterns. Diffuse DNA hypomethylation of malignant meningiomas readily facilitated their identification from lower grade tumors by unsupervised clustering. All clusters and 12/12 meningioma-dura pairs exhibited hypomethylation of the gene promoters of a module associated with the craniofacial patterning transcription factor FOXC1 and its upstream lncRNA FOXCUT. Furthermore, we identified an epigenetic continuum of increasing hypermethylation of polycomb repressive complex target promoters with increased histopathologic grade suggesting progressive epigenetic dysregulation is associated with increasing tumor aggressiveness. These findings are a starting point for future investigations of the role of epigenetic dysregulation of FOXC1 and cranial patterning genes in early stages of meningioma formation as well as studies of the utility of polycomb inhibitors for treatment of aggressive meningiomas.

ORGANISM(S): Homo sapiens

PROVIDER: GSE176457 | GEO | 2023/06/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

DNA Methylation Signatures Differentiate Meningiomas from Normal Dura [HumanMethylation450]

Project description:Meningiomas are the most common primary brain tumor. Though typically benign with a low mutational burden, histopathologic analysis has poor predictive value for malignant behavior and there are no proven chemotherapies. Although DNA methylation patterns distinguish subgroups of meningiomas and have higher predictive value for tumor behavior than histologic classification, little is known about differences in DNA methylation between meningiomas and surrounding normal dura tissue. Using multimodal studies of meningioma/dura pairs, we identified 4 distinct DNA methylation patterns. Diffuse DNA hypomethylation of malignant meningiomas readily facilitated their identification from lower grade tumors by unsupervised clustering. All clusters and 12/12 meningioma-dura pairs exhibited hypomethylation of the gene promoters of a module associated with the craniofacial patterning transcription factor FOXC1 and its upstream lncRNA FOXCUT. Furthermore, we identified an epigenetic continuum of increasing hypermethylation of polycomb repressive complex target promoters with increased histopathologic grade suggesting progressive epigenetic dysregulation is associated with increasing tumor aggressiveness. These findings are a starting point for future investigations of the role of epigenetic dysregulation of FOXC1 and cranial patterning genes in early stages of meningioma formation as well as studies of the utility of polycomb inhibitors for treatment of aggressive meningiomas.

2023-06-22 | GSE178139 | GEO

Multisite methylation profiling of primary human meningioma

Project description:Multiple stereotatically separate sites from human meningioma were processed for methlyation profiling Meningiomas are the most common primary intracranial tumors, but the molecular drivers of meningioma tumorigenesis are poorly understood. We hypothesized that investigating intratumor heterogeneity in meningiomas would elucidate biologic drivers and reveal new targets for molecular therapy. To test this hypothesis, we performed multiplatform molecular profiling of 86 spatially-distinct samples from 13 human meningiomas. Our data reveal that regional alterations in chromosome structure underlie clonal transcriptomic, epigenomic, and histopathologic signatures in meningioma. Stereotactic co-registration of sample coordinates to preoperative magnetic resonance images further demonstrated that high apparent diffusion coefficient (ADC) distinguished meningioma regions with proliferating cells enriched for developmental gene expression programs. To understand the function of these genes in meningioma, we developed a human cerebral organoid model of meningioma and validated the high ADC marker genes CDH2 and PTPRZ1 as potential targets for meningioma therapy using live imaging, single cell RNA sequencing, CRISPR interference, and pharmacology.

2020-06-17 | GSE151067 | GEO

Whole genome expression in meningioma

Project description:We performed expression profiling of 24 meningioma and two dura controls analyzing 55000 transcripts including 18300 known genes. We compared expression in meningioma vs. dura, expression of low grade (WHO I) vs. higher-grade (WHO II and WHO IIII) tumors and expression of meningothelial and syncytial meningioma vs. fibroblastic meningioma. Gene expression was analysed in 24 meningioma including eight of each WHO grade and two dura controls analyzing 55000 transcripts including 18300 known genes.

2008-11-20 | E-GEOD-12530 | biostudies-arrayexpress

Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities (array)

Project description:We report DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, proteomic, and single-cell approaches to show meningiomas are comprised of 3 groups with distinct clinical outcomes, biological drivers, and therapeutic vulnerabilities. Merlin-intact meningiomas have the best outcomes and are distinguished by NF2/Merlin regulation of glucocorticoid signaling, apoptosis, and susceptibility to cytotoxic therapy. Immune-enriched meningiomas have intermediate outcomes and are distinguished by immune infiltration, HLA expression, and lymphatic vessels. Hypermitotic meningiomas have the worst outcomes and are distinguished by convergent genetic and epigenetic mechanisms driving the cell cycle and resistance to cytotoxic therapy. Our results establish a framework for understanding meningioma biology, and provide a foundation for new meningioma treatments.

2022-01-10 | GSE183647 | GEO

Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features

Project description:This study reports clinical, genetic, epigenetic, gene expression, and cellular features distinguishing meningioma DNA methylation subgroups within meningioma DNA methylation groups. We present these data in the context of molecular and clinical models predicting postoperative outcomes across 565 meningiomas with comprehensive clinical follow-up from independent discovery and validation institutions. By discovering meningioma DNA methylation subgroups within meningioma DNA methylation groups, we provide an opportunity to resolve inconsistencies in the recent literature. In doing so, our study establishes an architecture that unifies opposing biological theories for the most common primary intracranial tumor

2022-10-10 | GSE212666 | GEO

Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies [RNA-Seq]

Project description:Purpose: Clustering of meningiomas using DNA methylation and RNA-sequencing data yields groups which predict clinical behavior than the current clinical standard of histopathologic grading. Both techniques segregate many common genomic features seen in meningiomas similarly, raising the question of whether they were identifying the same underyling groups. Methods: DNA methylation profiling (EPIC 850K array) and RNA-sequencing of 110 primary meningiomas was performed. Unsupervised clustering was performed using each type of data, followed by computational modeling which explored correlations of promoter methylation and copy number variation (CNV) with gene expression. Results: We performed unsupervised clustering of the DNA methylation data and gound three clusters to be optimal. These clusters aligned closely with our prior transcriptional classification (Patel et al. PNAS 2019). These groups also closely aligned with groups defined by large-scale cytogenetic changes and merlin expression/genomic instability, suggesting the presence of three biologic groups of meningioma that can be identified by multiple methods. Computational modeling demonstrated that both promoter methylation and CNV correlated closely with gene expression differences seen in meningioma and our biologic groups, although cytogenetic changes (particularly chr 1p loss) was predominant in the clinically aggressive tumors. Conclusions: Our anaylsis suggests the presence of three biologic groups of meningioma (MenG A, B, and C) which can be accurately identified through DNA methylation, RNA-seq, and cytogenetic profiling.

2021-11-30 | GSE189672 | GEO

Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies [Methylation array]

Project description:Purpose: Clustering of meningiomas using DNA methylation and RNA-sequencing data yields groups which predict clinical behavior than the current clinical standard of histopathologic grading. Both techniques segregate many common genomic features seen in meningiomas similarly, raising the question of whether they were identifying the same underyling groups. Methods: DNA methylation profiling (EPIC 850K array) and RNA-sequencing of 110 primary meningiomas was performed. Unsupervised clustering was performed using each type of data, followed by computational modeling which explored correlations of promoter methylation and copy number variation (CNV) with gene expression. Results: We performed unsupervised clustering of the DNA methylation data and gound three clusters to be optimal. These clusters aligned closely with our prior transcriptional classification (Patel et al. PNAS 2019). These groups also closely aligned with groups defined by large-scale cytogenetic changes and merlin expression/genomic instability, suggesting the presence of three biologic groups of meningioma that can be identified by multiple methods. Computational modeling demonstrated that both promoter methylation and CNV correlated closely with gene expression differences seen in meningioma and our biologic groups, although cytogenetic changes (particularly chr 1p loss) was predominant in the clinically aggressive tumors. Conclusions: Our analysis suggests the presence of three biologic groups of meningioma (MenG A, B, and C) which can be accurately identified through DNA methylation, RNA-seq, and cytogenetic profiling.

2021-11-30 | GSE189521 | GEO

Single-cell RNA sequencing of meningiomas

Project description:We report single-cell RNA sequencing of 57,114 cells from 8 meningioma samples and 2 dura samples, which are used to analyze the inter- and intra-meningioma heterogeneity across DNA methylation groups.

2022-01-10 | GSE183655 | GEO

Whole genome expression in meningioma

2008-11-21 | GSE12530 | GEO

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas [array]

Project description:RNA polymerase II mediates the transcription of all protein-coding genes in eukaryotic cells, a process that is fundamental to life. Genomic mutations in this enzyme have not been previously linked to any pathology in humans, a testament to its indispensable role in cell biology. Based on a combination of next-generation genomic analyses of 775 meningiomas, we report that recurrent somatic p.Gln403Lys or p.Leu438_His439del mutations in POLR2A, which encodes the catalytic subunit of RNA polymerase II, are sufficient to hijack this essential enzyme and drive neoplasia. POLR2A mutant tumors reveal dysregulation of key meningeal identity genes, including WNT6 and ZIC1/ZIC4. In addition to POLR2A, NF2, SMARCB1, TRAF7, KLF4, AKT1, PIK3CA and SMO, we also report somatic mutations in AKT3, PIK3R1, PRKAR1A, and SUFU in meningiomas. Our results identify a role for essential transcriptional machinery in driving tumorigenesis and define mutually exclusive meningioma subgroups with distinct clinical and pathological features. Expression microarray data from 121 total samples, including 96 tumors representing the major meningioma mutation groups (NF2/chr22 loss, POLR2A, KLF4/TRAF7, PI3K mutant, Sonic Hedgehog mutant) and 25 control samples (3 dura, 13 adult meninges, and 9 embryonic meninges).

2016-08-21 | E-GEOD-84263 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data